IP Library Granted Patent US 10,392,417
Granted Patent B2
US 10,392,417 · App. 15/797,498 · Granted Aug 27, 2019

Polymorph of regadenoson and process for preparation thereof

Inventors: Ravishanker Kovi (Monroe, NJ); Jayaraman Kannapan (Gujarat, IN); Ananda Babu Thirunavakarasu (Gujarat, IN); Piyush D. Fadadu (Gujarat, IN); Piyush B. Thumar (Gujarat, IN)
Assignee: Apicore US LLC
C07H19/16C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,392,417
App. No.
15/797,498
Granted
Aug 27, 2019
Kind
B2
Abstract

Processes are provided for the preparation of a stable polymorphic form C of regadenoson, the process involving steps of a) obtaining a solution of regadenoson in benzyl alcohol solvent, b) maintaining the reaction mixture of step a) to about 10° C. to about 90° C., and c) isolating the stable polymorphic form C of regadenoson. Polymorphic form C may be characterized by an x-ray powder diffraction pattern with peaks at about 6.1, 10.2, 10.6, 19.0 and 25.4.±0.2 degrees 2-theta.

Claims (7)

1. A process for the preparation of stable polymorphic form C of regadenoson, comprising the steps of:

a) obtaining a solution of Regadenoson in benzyl alcohol solvent;

b) maintaining the reaction mixture of step a) to about 10° C. to about 90° C.; and

c) isolating the stable polymorphic form C of regadenoson.

2. The process of claim 1 , wherein in step b), the mixture is heated to a temperature from about 70° C. to about 75° C.

3. The process of claim 1 , wherein in step c), the mixture is cooled to a temperature of about 25° C. to about 30° C.

4. The process of claim 1 , wherein the obtained stable polymorph form C has purity greater than 99%.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2026
From: MYLAN LABORATORIES LIMITED
To: MATRIX PHARMACORP PRIVATE LIMITED
Reel/Frame 075291/0584 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2026
From: MYLAN PHARMACEUTICALS INC.
To: MYLAN LABORATORIES LIMITED
Reel/Frame 075206/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2021
From: MYLAN API US LLC
To: MYLAN PHARMACEUTICALS INC.
Reel/Frame 057686/0024 →
CHANGE OF NAME Recorded Oct 4, 2021
From: APICORE US LLC
To: MYLAN API US LLC
Reel/Frame 057697/0758 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2017
From: KOVI, RAVISHANKER; KANNAPAN, JAYARAMAN; THIRUNAVAKARASU, ANANDA BABU; FADADU, PIYUSH D.; THUMAR, PIYUSH B.
To: APICORE US LLC
Reel/Frame 044532/0298 →
Priority Claims (1)
IN 201621037803 · Nov 4, 2016 · national
Continuity (1)
Related Publication 20180127452A1 · May 10, 2018